Who
Yong Ben
Chief Med & Dev Officer
Company insider
Files Form 4 as: Chief Med & Dev Officer, BridgeBio Oncology Therapeutics; Director, Corbus Pharmaceuticals Holdings.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $31K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 6 Mar 2023
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,1251,047 at $3.94 | filing |
| 14 Sep 2026filed 15 Sep 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Sold | $16K2,000 at $7.84 | filing |
| 14 Sep 2026filed 15 Sep 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Sold | $16K2,000 at $7.84 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,1671,047 at $7.80 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,1671,047 at $7.80 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,300 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,300 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 1 Apr 2026filed 5 May 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,4541,047 at $9.03 | filing |
| 1 Apr 2026filed 5 May 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,4541,047 at $9.03 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code A | —46,670 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code A | —46,670 at $0.00 | filing |
| 26 Aug 2025filed 28 Aug 2025 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —357,177 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —4,800 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —2,783 at $0.00 | filing |
| 16 May 2024filed 20 May 2024 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,783 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.